http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019509305-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2017-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019509305-A |
| titleOfInvention | Naftirizine as an integrin antagonist |
| abstract | The invention has αvβ6 integrin antagonist activity, Formula (I): wherein R 1, R 2 and R 3 are as described in the description and in the claims, respectively. Or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and to the treatment of diseases or conditions for which an αvβ6 integrin antagonist is indicated, in particular idiopathic pulmonary fibrosis. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in a therapy comprising. |
| priorityDate | 2016-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 502.